Mugoni, Vera
Panella, Riccardo
Cheloni, Giulia
Chen, Ming
Pozdnyakova, Olga
Stroopinsky, Dina
Guarnerio, Jlenia
Monteleone, Emanuele http://orcid.org/0000-0001-7440-900X
Lee, Jonathan David
Mendez, Lourdes
Menon, Archita Venugopal
Aster, Jon Christopher
Lane, Andrew A.
Stone, Richard Maury
Galinsky, Ilene
Zamora, José Cervera
Lo-Coco, Francesco
Bhasin, Manoj Kumar
Avigan, David
Longo, Letizia
Clohessy, John Gerard http://orcid.org/0000-0001-5186-9775
Pandolfi, Pier Paolo http://orcid.org/0000-0002-5352-5295
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA197529, R01CA142874)
Article History
Received: 16 August 2018
Accepted: 12 March 2019
First Online: 25 April 2019
Competing interests
: P.P.P. is a member of the Scientific Advisory Board of Agios Pharmaceuticals, Cambridge, MA. P.P.P., V.M., J.G.C. and M.C. have filed a U.S. Patent Application No. 62/593,761, entitled “ARSENIC TRIOXIDE AND RETINOIC ACID COMPOUNDS FOR TREATMENT OF IDH2-ASSOCIATED DISORDERS”, filed December 1, 2017. This application is still pending. The remaining authors declare no competing interests.